Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AusAm Biotechnologies Inc.

This article was originally published in Start Up

Executive Summary

Three-year-old AusAm Biotechnologies is actively pursuing both diagnostics and therapeutics, with all novel technologies based on its founding scientists' observations about the kidney. In diagnostics, it recently received FDA clearance for a highly sensitive test that detects precursors to kidney disease. The test has potential to become a wide screen, particularly for at-risk diabetics. In therapeutics, it is developing a polysaccharide-based class of anti-viral attachment inhibitors, which have potential in treatment of infectious diseases like AIDs, encephalitis and small pox.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts